Læknablaðið - 01.04.1969, Qupperneq 67

New in drop form MOGADON
The new way, the surer way to treat sleep disorders
!• NEW. <Mogadon> possesses a new
etiotropic action. in therapeutic
doses it exerts a selective depressant
action on the structures of the limbic
system without markedly affecting
•he other areas of the brain.This has
the effect of screening the physio-
togical mechanism which controls the
°nset of sleep from disturbing emo-
tional stimuli. The result: deeper
sleep. Conventional hypnotics depress
the entire central nervous system,
felatively indiscriminantly inhibiting
all areas of the brain, thus inducing a
ftiniature anesthesia in the patient.
2. SURE. <Mogadon> is particularly
well tolerated and possesses only
minimal toxicity.The safety margin
is exceptionally wide: an overdose of
100-300 mg (i.e. 20-60 times the
normal therapeutic dose) which with
conventional hypnotics would lead to
profound coma or death merely
results in a more prolonged period of
deep sleep with relaxed musculature,
relaxed breathing and normal cir-
culation. Risk of accidental or inten-
tional poisoning is therefore rcduced
to an absolute minimum.
3. EFFECTIVE. As double-blind tests
have confirmed, <Mogadon> has been
proved to be either as good as or
supcrior to the best known hypnotics
of the present day in rapidity of
onset, duration and depth of sleep
and condition on waking up. The onset
of sleep is swift but natural. The
patient sleeps soundly but is readily
roused. He wakes refreshed with no
‘hangover’.
(Mogadon) is aTrade Mark
F. Hoffmann-La Roche & Co. Ltd,
Basle, Switzerland